NanoViricides Reports Promising Anti-Measles Results for Broad-Spectrum Antiviral Candidate NV-387

NanoViricides, Inc. announced that CEO Dr. Anil Diwan discussed significant progress in the company's antiviral research during a video interview available at https://youtu.be/m_3Yk4_832E. The interview highlighted compelling data showing that NanoViricides' lead drug candidate, NV-387, exhibited potent anti-Measles activity in both cell culture studies and humanized animal models. These findings are particularly significant given the current absence of approved treatments for Measles, a highly contagious viral disease that continues to cause outbreaks worldwide.

The preclinical results demonstrated that NV-387 extended survival by 130% in severe infection models and provided substantial protection to lung tissue during advanced disease stages. This level of efficacy suggests NV-387 could address a critical unmet medical need in global public health. The drug candidate has already completed Phase I human clinical trials with no reportable adverse events, establishing a solid safety profile as it progresses toward more advanced development stages. The company is currently preparing to advance NV-387 into Phase II clinical trials for MPox treatment, while simultaneously exploring its potential application for Measles.

NanoViricides is strategically positioned to support Food and Drug Administration emergency use applications and investigator-initiated Investigational New Drug applications for urgent Measles cases. This capability could prove crucial during Measles outbreaks where rapid intervention is necessary to control transmission and reduce severe complications. The company's platform technology, licensed from TheraCour Pharma, Inc., enables the development of special purpose nanomaterials designed specifically for antiviral therapy. Additional information about the company's technology and programs can be found at https://www.nanoviricides.com.

NV-387 represents a broad-spectrum antiviral approach that the company plans to develop for multiple respiratory viral infections including RSV, COVID, Long COVID, and Influenza, in addition to MPox/Smallpox infections. The demonstrated activity against Measles virus expands the potential applications of this drug candidate and highlights the versatility of the nanoviricide technology platform. The company holds exclusive worldwide perpetual licenses for this technology across multiple viral disease categories, providing a comprehensive foundation for developing treatments against various viral pathogens.

The implications of these findings extend beyond Measles treatment alone. Success with NV-387 could validate NanoViricides' platform technology approach, potentially enabling faster development of treatments for other viral diseases in the company's pipeline. These include Shingles, oral and genital Herpes, viral eye diseases, various influenza strains, HIV, Hepatitis C, and emerging threats like Ebola virus. The broad-spectrum nature of NV-387 suggests it could become an important tool in pandemic preparedness, offering potential utility against multiple viral threats with a single therapeutic approach. The latest updates and information about NanoViricides' progress are available at https://ibn.fm/NNVC.

While the path to drug approval remains lengthy and requires substantial additional clinical validation, the positive preclinical results against Measles combined with the established safety profile from Phase I trials position NV-387 as a promising candidate in the antiviral therapeutic landscape. The potential availability of an effective Measles treatment would represent a significant advancement in managing this persistent global health challenge, particularly in regions experiencing outbreaks or where vaccination coverage remains incomplete.